ABBV-637

DRUG2 trials

Sponsors

AbbVie, Memorial Sloan Kettering Cancer Center

Conditions

Advanced Solid Tumors CancerGlioblastomaGliosarcomaNon Small Cell Lung Cancer (NSCLC)

Phase 1

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Active, not recruitingNCT04721015

AbbVieAdvanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)

Start: 2021-02-23End: 2026-02-28Updated: 2025-07-03

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

RecruitingNCT06934889

Memorial Sloan Kettering Cancer CenterGlioblastoma, Gliosarcoma

Start: 2025-04-07End: 2028-04-01Target: 60Updated: 2026-09-09